Teva Pharmaceutical Industries (TEVA) Free Cash Flow Growth (3y) (2012 - 2026)
Teva Pharmaceutical Industries (TEVA) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn | 39.19% |
| 10 | Vireo Growth | 10.48 Bn | 10.33 Bn | 59.30 Mn | 31.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.86% |
| Dec 31, 2025 | 6.93% |
| Sep 30, 2025 | -17.90% |
| Jun 30, 2025 | 226.33% |
| Mar 31, 2025 | -4.04% |
| Dec 31, 2024 | 13.75% |
| Sep 30, 2024 | 12.48% |
| Jun 30, 2024 | -61.48% |
| Mar 31, 2024 | 23.55% |
| Dec 31, 2023 | 90.11% |
| Sep 30, 2023 | -42.24% |
| Jun 30, 2023 | 13.02% |
| Mar 31, 2023 | -53.33% |
| Dec 31, 2022 | 25.64% |
| Sep 30, 2022 | 39.23% |
| Jun 30, 2022 | 77.23% |
| Mar 31, 2022 | -151.17% |
| Dec 31, 2021 | 25.31% |
| Sep 30, 2021 | 10.74% |
| Jun 30, 2021 | 59.25% |